DUBLIN, Feb. 19, 2024 /PRNewswire/ — The “Bioactive Wound Management – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Bioactive Wound Management Market to Reach $3.5 Billion by 2030 The global market for Bioactive Wound Management…
Month: February 2024
BARCELONA, España, 19 de febrero de 2024 /PRNewswire/ — Fractus, empresa pionera en tecnología de antenas con sede en Barcelona (España), anuncia con orgullo la resolución de su litigio de patentes con Vivint, una de las principales empresas del sector de la seguridad doméstica…
BARCELONA, España, 19 de febrero de 2024 /PRNewswire/ — Fractus, empresa pionera en tecnología de antenas con sede en Barcelona (España), anuncia con orgullo la resolución de su litigio de patentes con Vivint, una de las principales empresas del sector de la seguridad doméstica…
BARCELONA, España, 19 de febrero de 2024 /PRNewswire/ — Fractus, empresa pionera en tecnología de antenas con sede en Barcelona (España), anuncia con orgullo la resolución de su litigio de patentes con Vivint, una de las principales empresas del sector de la seguridad doméstica…
DUBLIN, Feb. 19, 2024 /PRNewswire/ — The “Welding Fume Extraction Equipment – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Welding Fume Extraction Equipment Market to Reach $6.3 Billion by 2030 The global market for Welding Fume…
DUBLIN, Feb. 19, 2024 /PRNewswire/ — The “Welding Fume Extraction Equipment – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Welding Fume Extraction Equipment Market to Reach $6.3 Billion by 2030 The global market for Welding Fume…
DUBLIN, Feb. 19, 2024 /PRNewswire/ — The “Welding Fume Extraction Equipment – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Welding Fume Extraction Equipment Market to Reach $6.3 Billion by 2030 The global market for Welding Fume…
WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ — Neurophth Therapeutics, Inc. (“Neurophth”) announced today that the last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused by…
WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ — Neurophth Therapeutics, Inc. (“Neurophth”) announced today that the last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused by…
WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ — Neurophth Therapeutics, Inc. (“Neurophth”) announced today that the last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused by…